GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mezzion Pharma Co 140410.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

65,700

+4.95%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Mezzion Pharma Co

Its shares trade on KOSDAQ under the ticker 140410.KQ. It has been listed since 20 January 2012. In the fiscal year to 31 December 2025, it reported revenue of ₩7.91bn and a net loss of ₩34.93bn. At that date it held total assets of ₩98.02bn and shareholders' equity of ₩17.19bn.

Mezzion Pharma Co., Ltd. engages in the development, production, and licensing of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2012-01-20. The firm focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The firm has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
20 Jan 2012

Leadership

Pay as last reported

  • Mr. Dong Hyeon ParkChief Executive Officer, Director₩1.03bn
  • Beom Jin ChoiDirector
  • Mr. Peter MansoDirector
  • Dr. Mitchell SteinerDirector
  • Mr. James YeagerDirector
  • Mr. Jin Su YimDirector
  • Mr. Jeong Seok ChaeNon-Executive Independent Director
  • Mr. Bon Gwon GuNon-Executive Independent Director
  • Seong Yil NohIR Contact Officer, since 2021

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Mezzion Pharma Co Ltd possesses several strengths that give it a competitive advantage in the pharmaceutical industry. These strengths include:

Weaknesses

  • Despite its strengths, Mezzion Pharma Co Ltd also faces certain weaknesses, which may hinder its progress and growth. These weaknesses include:

Opportunities

  • Mezzion Pharma Co Ltd can capitalize on various opportunities in the pharmaceutical market to further enhance its position and profitability. These opportunities include:

Threats

  • While pursuing its goals, Mezzion Pharma Co Ltd faces certain threats that could impact its operations and market position. These threats include:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.